These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 8845864)

  • 1. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
    VandenBranden M; Ring BJ; Binkley SN; Wrighton SA
    Pharmacogenetics; 1996 Feb; 6(1):81-91. PubMed ID: 8845864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
    Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
    J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
    Chiba K; Kobayashi K; Manabe K; Tani M; Kamataki T; Ishizaki T
    J Pharmacol Exp Ther; 1993 Jul; 266(1):52-9. PubMed ID: 8331574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
    Heyn H; White RB; Stevens JC
    Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
    Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
    Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
    Abelö A; Andersson TB; Antonsson M; Naudot AK; Skånberg I; Weidolf L
    Drug Metab Dispos; 2000 Aug; 28(8):966-72. PubMed ID: 10901708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
    Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
    Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
    Taguchi K; Konishi T; Nishikawa H; Kitamura S
    Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
    Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
    Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
    Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
    Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
    Yamazaki H; Shimada T
    Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
    Gorski JC; Jones DR; Wrighton SA; Hall SD
    Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes.
    Liu ZQ; Zhu B; Tan YF; Tan ZR; Wang LS; Huang SL; Shu Y; Zhou HH
    J Pharmacol Exp Ther; 2002 Jan; 300(1):105-11. PubMed ID: 11752104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.
    Venkatakrishnan K; Greenblatt DJ; von Moltke LL; Schmider J; Harmatz JS; Shader RI
    J Clin Pharmacol; 1998 Feb; 38(2):112-21. PubMed ID: 9549641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.